Virginia Bio Welcomes Dr. Reg Seeto to Board of Directors
Wednesday, March 16, 2016
Virginia Bio, the premier statewide non-profit association representing life science industry in the Commonwealth of Virginia, elected Dr. Reg Seeto, Vice President, Head of Partnering and Strategy at MedImmune, the biologics research and development arm of AstraZeneca, as a new member of their Board of Directors for a term of three years.
“We are excited to have Reg Seeto join the Board,” said Jeff Conroy, Chairman, Virginia Bio Board of Directors. “His commitment to strengthening economic development relationships, advancing entrepreneurial efforts and contributing to building a top-tier life science ecosystem in the Commonwealth will be a great addition to our Board.”
Dr. Seeto joined MedImmune in 2008, and has held a number of leadership positions with the company during his tenure. In 2013, he assumed his current role on MedImmune’s leadership team, in which he established and now leads the company’s Partnering and Strategy group. During the past two years, Dr. Seeto and his team have completed more than 90 strategic business deals, ranging from acquisitions and clinical collaborations to licensing agreements and new industry partnerships. Dr. Seeto has also led his team in efforts to grow the bioscience ecosystems surrounding MedImmune’s key locations in California, Maryland, and the United Kingdom through strategic collaborations, regional events and activities.
Prior to MedImmune, Dr. Seeto was Vice President of Global Marketing for Schering Plough/Organon Biosciences and Executive Director of US Marketing for Boehringer Ingelheim Pharmaceuticals. Earlier in his career, he was a consultant at McKinsey & Company and started his career as a medical doctor involved in both clinical practice and research. He has published first author publications in peer reviewed journals and holds his medical degree from the University of Sydney, Australia. To see the full list of Virginia Bio board members visit vabio.org/leadership.